Albireo Pharma, Inc. / Fundamentals

    Income statement

    Net revenue
    €49.24M
    Cost of goods sold
    €2.19M
    Gross profit
    €47.06M
    SG&A expenses
    €67.58M
    R&D expenses
    €76.11M
    EBITDA
    -€88.19M
    D&A
    €368.08K
    EBIT
    -€105.46M
    Interest expenses
    €9.79M
    EBT
    -€115.77M
    Tax expenses
    €2.10M
    Net income
    -€117.87M

    Cash flow statement

    Net deferred tax
    €2.27M
    Non-cash items
    €16.84M
    Changes in working capital
    -€17.34M
    Operating cash flow
    -€98.95M
    Capex
    €1.06M
    Other investing cash flow
    €0.00
    Net investing cash flow
    -€1.06M
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €17.70M
    Debt repayment
    €0.00
    Other financing cash flow
    €109.85M
    Net financing cash flow
    €109.85M
    Foreign exchange effects
    -€1.62M
    Net change in cash
    €8.46M
    Cash at end of period
    €233.78M
    Free cash flow
    -€97.88M

    Balance sheet

    Cash and cash equivalents
    €190.88M
    Cash and short-term investments
    €190.88M
    Total receivables
    €1.74M
    Inventory
    €2.70M
    Other current assets
    €9.59M
    Total current assets
    €204.92M
    Property, plant & equipment
    €1.12M
    Goodwill
    €14.81M
    Intangible assets
    €0.00
    Long-term investments
    €0.00
    Other non-current assets
    €54.76M
    Total non-current assets
    €70.69M
    Total assets
    €275.61M
    Accounts payable
    €5.96M
    Short-term debt
    €0.00
    Other current liabilities
    €26.49M
    Total current liabilities
    €32.45M
    Long-term debt
    €0.00
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €157.30M
    Total non-current liabilities
    €157.30M
    Total liabilities
    €189.75M
    Common stock
    €177.61K
    Retained earnings
    -€361.25M
    Other equity
    €7.05M
    Total equity
    €85.86M
    Total liabilities and shareholders' equity
    €275.61M

    Company information

    Market capitalization
    €781.21M
    Employees
    130
    Enterprise Value
    €677.78M

    Company ratios

    Gross margin
    95.6% Much better than peer group: -80,784.7%
    EBITDA margin
    -179.1% Much better than peer group: -83,609.4%
    EBIT margin
    -214.2% Much better than peer group: -84,622.3%
    EBT margin
    -235.1% Much better than peer group: -83,984.0%
    Net margin
    -239.4% Much better than peer group: -84,631.4%
    ROE
    -137.3% Much better than peer group: -1,782.3%
    ROA
    -42.8% Much better than peer group: -1,216.7%
    Asset turnover
    17.9% Much worse than peer group: 39.8%
    FCF margin
    -203.1% Much better than peer group: -40,073.0%
    FCF yield
    -12.8%
    Efficiency ratio
    279.1%
    Net sales per employee
    €378.78K
    Net income per employee
    -€906.71K

    Notifications